Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI302 in nAMD and DME
NCT05961007Phase 2Suspended
- Sponsor
- Innovent Biologics
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efdamrofusp alfa in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME), sponsored by Innovent Biologics. Started Nov 2021; status: suspended.
02
Drugs
efdamrofusp alfa
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05961007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961007.